This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 1, 2004; 10(11): 1652-1655 Published online Jun 1, 2004. doi: 10.3748/wjg.v10.i11.1652
Table 1 Age distribution of the patient
Age range (yr)
Case number (n)
%
Under 20
18
9.89
21-30
45
24.73
31-40
35
19.23
41-50
29
15.93
51-60
18
9.89
Above 60
37
20.33
Table 2 Incidence rate of abnormal-liver-function outcomes
ALT
AST
LDH
Total cases (n)
182
182
139
Abnormal cases (n)
128
57
87
Ratio (%)
70.3
31.3
62.6
Table 3 Abnormal-liver-function outcomes before treatment vs after treatment
Cases (n)
ALT
AST
LDH
Before
After
Before
After
Before
After
Total
182
166
182
164
122
105
Normal
93
85
133
145
46
81
Abnormal
89
81
49
19
76
24
Table 4 Therapeutic drugs in 182 SARS patients
Antibiotics
Ribavirin
Methylpredisolone
Cases (n)
160
137
115
Rate of usage (%)
87.9
75.2
63.2
Table 5 The distribution of ribavirin treatment in 84 SARS patients
Treatment
Days 1-3
Days 4-5
Days 6-10
Days 11-20
Days 21-30
Days 30
Cases number
32
23
17
8
3
1
%
38.1%
27.4%
20.2%
9.5%
3.6%
1.2%
Citation: Cui HJ, Tong XL, Li P, Hao YX, Chen XG, Li AG, Zhang ZY, Duan J, Zhen M, Zhang B, Hua CJ, Gong YW. Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. World J Gastroenterol 2004; 10(11): 1652-1655